Assessing Vir Biotechnology: Insights From 5 Financial Analysts
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
评估Vir生物技术：来自5位金融分析师的见解
Vir Biotechnology (NASDAQ:VIR) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
在过去的三个月中，有5位分析师对Vir Biotechnology（纳斯达克股票代码：VIR）进行了分析，揭示了从看涨到看跌的不同观点。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
下表总结了他们最近的评估，说明了过去30天不断变化的情绪，并将其与前几个月进行了比较。
Analysts have set 12-month price targets for Vir Biotechnology, revealing an average target of $64.8, a high estimate of $110.00, and a low estimate of $9.00. This current average has increased by 22.26% from the previous average price target of $53.00.
分析师已经为Vir Biotechnology设定了12个月的目标股价，显示平均目标股价为64.8美元，最高估计为110.00美元，最低估计为9.00美元。目前的平均价格较之前的平均目标价53.00美元上涨了22.26％。
Deciphering Analyst Ratings: An In-Depth Analysis
解密分析师评级：深度分析
The standing of Vir Biotechnology among financial experts becomes clear with...
通过对近期分析师行为的...
登录免费看全文
登录/注册